These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 18381962)

  • 1. Loss of retinoblastoma tumor suppressor protein makes human breast cancer cells more sensitive to antimetabolite exposure.
    Derenzini M; Donati G; Mazzini G; Montanaro L; Vici M; Ceccarelli C; Santini D; Taffurelli M; Treré D
    Clin Cancer Res; 2008 Apr; 14(7):2199-209. PubMed ID: 18381962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The p53-mediated sensitivity of cancer cells to chemotherapeutic agents is conditioned by the status of the retinoblastoma protein.
    Derenzini M; Brighenti E; Donati G; Vici M; Ceccarelli C; Santini D; Taffurelli M; Montanaro L; Treré D
    J Pathol; 2009 Nov; 219(3):373-82. PubMed ID: 19731257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rho GDP dissociation inhibitor alpha expression correlates with the outcome of CMF treatment in invasive ductal breast cancer.
    Ronneburg H; Span PN; Kantelhardt E; Dittmer A; Schunke D; Holzhausen HJ; Sweep FC; Dittmer J
    Int J Oncol; 2010 Feb; 36(2):379-86. PubMed ID: 20043072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Over-expression of metallothionein predicts chemoresistance in breast cancer.
    Yap X; Tan HY; Huang J; Lai Y; Yip GW; Tan PH; Bay BH
    J Pathol; 2009 Mar; 217(4):563-70. PubMed ID: 19116991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
    Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I
    Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
    Dubsky P; Sevelda P; Jakesz R; Hausmaninger H; Samonigg H; Seifert M; Denison U; Mlineritsch B; Steger G; Kwasny W; Stöger H; Bartsch R; Stierer M; Taucher S; Fridrik M; Schippinger W; Greil R; Pötter R; Gnant M;
    Clin Cancer Res; 2008 Apr; 14(7):2082-7. PubMed ID: 18381948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow.
    Das JR; Fryar-Tita EB; Zhou Y; Green S; Southerland WM; Bowen D
    Anticancer Res; 2007; 27(6B):3791-9. PubMed ID: 18225534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raloxifene attenuation of 5-FU/methotrexate cytotoxicity in human breast cancer cells: the importance of sequence in combination chemotherapy.
    Fryar EB; Das JR; Davis JH; Desoto JA; Laniyan I; Southerland WM; Bowen D
    Anticancer Res; 2006; 26(3A):1861-7. PubMed ID: 16827118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
    Viale G; Regan MM; Mastropasqua MG; Maffini F; Maiorano E; Colleoni M; Price KN; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Gusterson BA; Castiglione-Gertsch M; Gelber RD; Goldhirsch A; Coates AS;
    J Natl Cancer Inst; 2008 Feb; 100(3):207-12. PubMed ID: 18230798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
    Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L
    Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
    Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
    J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated gene expression profile predicts prognosis of breast cancer patients.
    Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
    Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raloxifene attenuation of methotrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-FU/methotrexate.
    Das JR; Fryar EB; Epie NN; Southerland WM; Bowen D
    Anticancer Res; 2006; 26(3A):1877-83. PubMed ID: 16827120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profile.
    Mottolese M; Orlandi G; Sperduti I; Merola R; Buglioni S; Di Benedetto A; Pinnarò P; Perracchio L; Venturo I; Cognetti F; Cianciulli A
    Am J Surg Pathol; 2007 Feb; 31(2):247-54. PubMed ID: 17255770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression.
    Jacquemier J; Penault-Llorca F; Viens P; Houvenaeghel G; Hassoun J; Torrente M; Adélaïde J; Birnbaum D
    Anticancer Res; 1994; 14(6B):2773-8. PubMed ID: 7872717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer.
    Schrohl AS; Meijer-van Gelder ME; Holten-Andersen MN; Christensen IJ; Look MP; Mouridsen HT; Brünner N; Foekens JA
    Clin Cancer Res; 2006 Dec; 12(23):7054-8. PubMed ID: 17114213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
    Tzaida O; Gogas H; Dafni U; Kyroudi A; Papaspyrou I; Kyriakou V; Malamou-Mitsi V; Alamani M; Skopa C; Kostopoulos I; Kastritis E; Pectasides D; Briasoulis E; Kalofonos HP; Aravantinos G; Fountzilas G; Arapantoni-Dadioti P
    Oncology; 2007; 72(5-6):388-96. PubMed ID: 18187961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.